Organization
Radiomedix
2 clinical trials
Clinical trial
An Open-label, Single-dose, Single Arm, Single-center Clinical Trial of 64Cu(Copper)-DOTATATE (NETMedix™) PET-CT Scan for Imaging Patients With Known or Suspected Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)Status: Completed, Estimated PCD: 2019-03-23
Clinical trial
A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in Subjects With Somatostatin Receptor Expressing Neuroendocrine TumorsStatus: Recruiting, Estimated PCD: 2026-10-01